3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
6
Phase 1
5
Phase 1/2
3
Phase 3
2
Phase 2/3
2
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Lymphoid
2
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
2
Interventions
Cytarabine
166
Cyclophosphamide
110
Daunorubicin
88
Methotrexate
83
Etoposide
66
Vincristine
63
Mercaptopurine
55
Rituximab
54
Dexamethasone
54
venetoclax
50
fludarabine
47
Doxorubicin
46
Azacitidine
46
Idarubicin
45
Asparaginase
42
Imatinib Mesylate
41
Prednisone
39
pegaspargase
37
Thioguanine
36
Radiotherapy
35
Mitoxantrone
35
Busulfan
31
Peripheral Blood Stem Cell Transplantation
25
Leucovorin
25
Bendamustine Hydrochloride
25
fludarabine phosphate
24
Filgrastim
24
obinutuzumab
23
nilotinib
23
Granulocyte Colony-Stimulating Factor
23
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
ublituximab
×
Other hematologic neoplasm
×
Clear all
NCT02612311
2024-12-13
UNITY-CLL
TG Therapeutics, Inc.
Phase 3
Terminated
603 enrolled
17 charts
NCT02301156
2022-05-20
GENUINE
TG Therapeutics, Inc.
Phase 3
Completed
126 enrolled
18 charts